Correlation between nasal potential difference measurements, genotype and clinical condition in patients with cystic fibrosis

In cystic fibrosis (CF), the clinical condition of patients correlates poorly with genotype. One possible explanation is that clinical status is influenced by net preserved chloride secretion rather than the CF mutation. We tested the relationships between residual chloride secretion, as measured by nasal potential difference (PD) and the type of mutation (genotypes expressing apical cystic fibrosis transmembrane conductance regulator (CFTR) protein versus those that do not) and clinical status. Twenty two CF patients (mean age 25.7 yrs, 11 females and 11 males, mean forced expiratory volume in one second (FEV1) 53.1% of predicted) with defined genotypes were recruited. Nasal PD was measured using a standard protocol involving the perfusion of the nasal epithelium with a sodium channel blocker (amiloride), followed by a solution of low chloride and finally with isoprenaline. Patients with apical CFTR protein showed higher residual chloride secretion than those without (amiloride to isoprenaline value of 4.59 and 0.56 mV, respectively, p = 0.01). There was no correlation between mutation type and clinical condition. When these patients were recategorized as "high" (> 10 mV amiloride to isoprenaline response) or "low" (10 mV or less) chloride secretors, we found that the former group had a significantly higher FEV1 (67.7 versus 48.3% pred) and a better pulmonary radiological score (4.14 versus 7.07, by Northern scoring system). These results suggest that some cystic fibrosis patients, regardless of genotype, have an ability to secrete chloride when stimulated with chloride secretatagogues, and this is correlated with a better lung function. These results also have implications for the use of potential difference measurements in novel cystic fibrosis transmembrane conductance regulator replacement trials.

This article has been cited by other articles:

				S. M. Rowe, F. Accurso, and J. P. Clancy Detection of Cystic Fibrosis Transmembrane Conductance Regulator Activity in Early-Phase Clinical Trials Proceedings of the ATS, August 1, 2007; 4(4): 387 - 398. [Abstract] [Full Text] [PDF]

				F. Van Goor, K. S. Straley, D. Cao, J. Gonzalez, S. Hadida, A. Hazlewood, J. Joubran, T. Knapp, L. R. Makings, M. Miller, et al. Rescue of {Delta}F508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules Am J Physiol Lung Cell Mol Physiol, June 1, 2006; 290(6): L1117 - L1130. [Abstract] [Full Text] [PDF]

				P G Noone and K W Southern Unravelling salt transport in cystic fibrosis Thorax, November 1, 2004; 59(11): 916 - 917. [Full Text] [PDF]

				I Fajac, D Hubert, D Guillemot, I Honore, T Bienvenu, F Volter, J Dall'Ava-Santucci, and D J Dusser Nasal airway ion transport is linked to the cystic fibrosis phenotype in adult patients Thorax, November 1, 2004; 59(11): 971 - 976. [Abstract] [Full Text] [PDF]

				D. B. Salinas, N. Pedemonte, C. Muanprasat, W. F. Finkbeiner, D. W. Nielson, and A. S. Verkman CFTR involvement in nasal potential differences in mice and pigs studied using a thiazolidinone CFTR inhibitor Am J Physiol Lung Cell Mol Physiol, November 1, 2004; 287(5): L936 - L943. [Abstract] [Full Text] [PDF]

				H. L. Wallace, P. M. Barker, and K. W. Southern Nasal Airway Ion Transport and Lung Function in Young People with Cystic Fibrosis Am. J. Respir. Crit. Care Med., September 1, 2003; 168(5): 594 - 600. [Abstract] [Full Text] [PDF]

				Z. Bebok, A. Tousson, L. M. Schwiebert, and C. J. Venglarik Improved oxygenation promotes CFTR maturation and trafficking in MDCK monolayers Am J Physiol Cell Physiol, January 1, 2001; 280(1): C135 - C145. [Abstract] [Full Text] [PDF]

				J. M. PILEWSKI and R. A. FRIZZELL Role of CFTR in Airway Disease Physiol Rev, January 1, 1999; 79(1): 215 - 255. [Abstract] [Full Text] [PDF]